A first-in-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells (CSC) in patients with advanced solid tumors

Authors
Category Primary study
JournalEJC SUPPLEMENTS
Year 2010
This article has no abstract
Epistemonikos ID: 91f069b82db6ec079455190f82cca89cff45e5d3
First added on: Mar 01, 2025